Last reviewed · How we verify
Fertagyl (GONADORELIN)
Fertagyl (Gonadorelin) is a gonadorelin, a small molecule that targets the gonadotropin-releasing hormone receptor. It was originally developed and is currently owned by a pharmaceutical company. Fertagyl is FDA-approved for treating amenorrhea and as a diagnostic test for gonadotropin deficiency, with an approval date of 1982. The drug is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. As an off-patent drug, its commercial status is uncertain.
At a glance
| Generic name | GONADORELIN |
|---|---|
| Drug class | gonadorelin |
| Target | Gonadotropin-releasing hormone receptor |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Amenorrhea
- Diagnostic Test for Gonadotropin Deficiency
Common side effects
Key clinical trials
- Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (NA)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study) (NA)
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
- PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fertagyl CI brief — competitive landscape report
- Fertagyl updates RSS · CI watch RSS